RegCell Secures $44 Million Series A Financing to Advance Treg Cell Therapies for Autoimmune Diseases

  FTI portfolio company, RegCell (Headquarters: Emeryville, CA; CEO: Michael McCullar), a biotechnology company developing regulatory T cell (Treg) therapies to restore immune tolerance and treat autoimmune diseases, has closed a $44 million Series A financing. Combined with a $22 million non-dilutive award from Japan’s Agency for Medical Research and Development (AMED), RegCell has secured approximately $66 million in new funding.  The Series A was led by Playground Global, with participation from Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures, and Medical Incubator Japan, alongside existing investors including FTI, The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, and Kyoto University Innovation Capital. FTI first invested in RegCell as a co-lead of the company’s Seed extension round in November 2024. Koji Yasuda, Principal at FTI continues to serve as an Outside Director on RegCell’s BoD. Proceeds will support clinical advancement including an Investigational New Drug (IND) submission, development of a  second-generation epigenetic reprogramming platform, and support expansion of the clinical pipeline through an additional Phase 2 proof-of-concept study. RegCell’s therapeutic platform is based on the discovery of Tregs by Nobel Laureate and co-founder, Professor Shimon Sakaguchi.   Related Coverage Business Wire - RegCell Secures $66 Million of Additional Funding Endpoints News  - RegCell Lands $44M Series A to Take Nobel-Winning Tregs Into the Clinic  

About RegCell, Inc. Headquartered in San Francisco, CA, with R&D operations in Japan, RegCell, Inc. is a biotechnology company developing regulatory T cell (Treg) therapy to restore immune tolerance (immune cell balance) to treat autoimmune diseases. Founded on the  discoveries of Dr. Shimon Sakaguchi, the company’s platform epigenetically reprograms T cells into disease-modifying Tregs and is advancing toward global clinical trials and commercial partnerships. For more information, visit www.regcellbio.com   About Fast Track Initiative:   Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan. Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/